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The cancer risk is unknown for those families in which a microsatellite instable tumour is neither explained by MLH1 promoter
methylation nor by a germline mutation in a mismatch repair (MMR) gene. Such information is essential for genetic counselling.
Families suspected of Lynch syndrome (n¼614) were analysed for microsatellite instability, MLH1 promoter methylation and/or
germline mutations in MLH1, MSH2, MSH6, and PMS2. Characteristics of the 76 families with a germline mutation (24 MLH1,2PMS2,
32 MSH2, and 18 MSH6) were compared with those of 18 families with an unexplained microsatellite instable tumour. The mean age
at diagnosis of the index patients in both groups was comparable at 44 years. Immunohistochemistry confirmed the loss of an MMR
protein. Together this suggests germline inactivation of a known gene. The Amsterdam II criteria were fulfilled in 50/75 families (66%)
that carried a germline mutation in an MMR gene and in only 2/18 families (11%) with an unexplained microsatellite instable tumour
(Po0.0001). Current diagnostic strategies can detect almost all highly penetrant MMR gene mutations. Patients with an as yet
unexplained microsatellite instable tumour likely carry a different type of mutation that confers a lower risk of cancer for relatives.
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Lynch syndrome (Hereditary NonPolyposis Colorectal Cancer
(HNPCC)) accounts for about 5% of colorectal cancers and is
caused by a germline mutation in one of the mismatch repair
(MMR) genes (Aaltonen et al, 1998; Cunningham et al, 2001; Lynch
and de la Chapelle, 2003; Hampel et al, 2005; Barnetson et al,
2006). Known MMR genes causing Lynch syndrome are MLH1,
PMS2, MSH2, and MSH6. Typical Lynch syndrome families show
autosomal dominant predisposition to a number of cancers of
which colorectal cancer is the most important. Conversely, over
90% of colorectal cancers of Lynch syndrome patients have a
defect in the MMR system (Lynch and de la Chapelle, 2003).
Failure of the DNA MMR system causes microsatellite instability
(MSI) in tumours.
MSI reflects either the presence of a germline mutation in the
MMR system or somatic hypermethylation of the promoter region
of the MLH1 gene (Cunningham et al, 2001). Patients with a
tumour with MSI and somatic hypermethylation of the MLH1
promoter rarely carry a germline mutation in the MMR system,
although rare exceptions have been reported. A few families have
been described in which Lynch syndrome patients display
hypermethylation of the MLH1 promoter in tumour as well as in
non-tumour tissue (Gazzoli et al, 2002; Miyakura et al, 2004; Suter
et al, 2004; Hitchins et al, 2005; Valle et al, 2007a). In addition, a
family was recently described in which the susceptibility to
tumours is caused by germline methylation of the MSH2 promoter
(Chan et al, 2006). Taken together, hypermethylation of the MLH1
promoter indicates a very low likelihood that Lynch syndrome is
the cause of the MSI (Samowitz et al, 2005; Weisenberger et al,
2006). Such patients can be offered less stringent surveillance
programs (Lindor et al, 2005; Dove-Edwin et al, 2006; Valle et al,
2007b).
Little is known about the cancer risk in those families in which
MSI is detected in a tumour, but where the MSI can be explained
neither by hypermethylation of the MLH1 promoter nor by a
germline mutation in an MMR gene. Such information is essential
for genetic counselling.
In the present study, we examined patients with a tumour that
indicated possible Lynch syndrome for germline mutations in the
MMR genes MLH1, MSH2, MSH6, and PMS2. In addition, we tested
tumour DNA for hypermethylation of the MLH1 promoter. Most of
these patients were preselected by MSI analysis. Family character-
istics of the patients with an MMR germline mutation were
compared with those of patients with an unexplained microsatellite
instable tumour.
MATERIALS AND METHODS
Patients
We examined 614 families, who visited the Department of Human
Genetics of the Radboud University Nijmegen Medical Centre
Received 29 January 2007; revised 26 March 2007; accepted 26 March
2007; published online 24 April 2007
*Correspondence: Dr MJL Ligtenberg;
E-mail: M.Ligtenberg@antrg.umcn.nl
British Journal of Cancer (2007) 96, 1605–1612
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sbetween 1997 and November 2005 because of possible familial
colorectal cancer. Families were included because they either
fulfilled the Amsterdam II criteria (Vasen et al, 1999) (n¼126), or
fulfilled the Bethesda guidelines (Rodriguez-Bigas et al, 1997)
(n¼333), or had a history very close to the Bethesda guidelines
(n¼155). Such patients are suspected of Lynch syndrome, which
is defined as cancer owing to a germline mutation in one of the
MMR genes (Jass, 2006).
Two diagnostic molecular strategies were used. Mutation
analysis of germline DNA was performed as the first test in 83
families, who fulfilled clinical criteria for Lynch syndrome, or in
which no tumour material was available. MSI analysis was also
performed in 43 of these families. In the other 531 families MSI
analysis was used as the initial step to select patients for germline
mutation analysis.
The index tumour of a family was defined as the MSI-positive
tumour that was diagnosed at the youngest age or, in case MSI
analysis was not performed, the first tumour of the patient in
whom the germline mutation was detected. The study was
performed in accordance with the rules of the Radboud University
Nijmegen Medical Centre Medical Ethical Committee.
Germline mutation analysis of the MMR system
Mutation analysis of MLH1, PMS2, MSH2, and MSH6 was
performed in DNA from peripheral blood lymphocytes by a
combination of either single-strand conformation polymorphism
analysis or denaturing gradient gel electrophoresis and direct
sequence analysis essentially as described elsewhere (Wu et al,
1997; Hoogerbrugge et al, 2003). Only mutations resulting in a
premature termination codon, the recurrent amino-acid deletion
in MLH1 c.1852_1854del (p.Lys618del) and the amino-acid
deletion c.211_213del (p.Glu71del) in MLH1, which has been
shown to abort the function of MLH1 (Raevaara et al, 2002), were
considered pathogenic. For the detection of large deletions and
duplications in MLH1, MSH2, MSH6, and PMS2, the P003 and P008
Multiplex Ligation-dependent Probe Amplification (MLPA) kits
of MRC Holland (Amsterdam, the Netherlands) were used. All
deletions and duplications were confirmed by Southern blot
analysis essentially as described elsewhere (Wijnen et al, 1998) or
with a specific PCR using primers flanking the deletion or one of
the breakpoints of a duplicated region.
MSI analysis
In total, 667 tumours in 574 families were tested for MSI: 566
colorectal carcinomas, 34 colorectal adenomas, 47 endometrium
carcinomas, eight duodenum/small bowel/appendix carcinomas,
one sebaceous carcinoma and one other skin tumour (tricho-
epithelioma or trichoblastoma), one ovarian carcinoma, and nine
urothelial cell carcinomas.
MSI analysis was performed using the Bethesda panel of
microsatellite markers (D2S123, D5S346, D17S250, BAT25,
BAT26) (Boland et al, 1998). Tumours were scored as MSI positive
if at least two of the five Bethesda markers showed instability; they
were scored MSI negative if none of the Bethesda markers showed
instability. In case of one instable marker, additional markers
were included, and immunohistochemistry (IHC) of MMR proteins
was performed (Hoogerbrugge et al, 2003). In 273 tumours, the
mononucleotide marker BAT40 was added to the standard set of
markers and in 558 of 667 tumours IHC of MSH6 was performed
irrespective of the MSI status to minimise the chance of missing a
tumour that was due to an MSH6 germline mutation.
Immunohistochemistry
IHC was performed on formalin-fixed, paraffin-embedded tissues.
Slides were stained with antibodies against MLH1 (Pharmingen
code: 51-1327gr), PMS2 (Pharmingen code: 556415), MSH2
(Oncogene Research Products code: NA26), and MSH6 (Transduc-
tion Laboratories code: G70220). Staining patterns of MMR
proteins were evaluated using normal epithelial, stromal, and
inflammatory cells as internal controls. Stained slides were scored
as (1) positive, that is showing nuclear staining in at least some
tumour cells; (2) negative, that is no staining of the tumour with a
positive internal control; or (3) not assessable, that is when the
technical quality was insufficient to provide an unambiguous
result despite repeated assays (de Jong et al, 2004).
Analysis of hypermethylation of the MLH1 promoter
The DNA methylation status of the MLH1 promoter region was
determined after bisulphite treatment of the DNA using the EZ
DNA methylation KITt, ZYMO Research. To avoid conversion of
methylated cytosines to uracil, the modification time was
optimised. Modification was performed in duplicate for 3 and
6h, respectively. Methylation of the region of 337–154bp
upstream of the translational start site, which has been shown to
correlate with MLH1 expression, was analysed (Deng et al, 2002).
FAM-labelled PCR products were generated using primers (50-
TATTTTTGTTTTTATTGGTTGGATA-30 and 50-AATACCAATCAA
ATTTCTCAACTCT-30) flanking 11 CpG sites and analysed on an
ABI PRISM 3730 Genetic Analyzer under denaturing conditions
using genemapper software. The products of unmethylated and
methylated DNA migrate at 186 and 183bp, respectively. This was
verified by digestion by BstUI (New England Biolabs, Beverly, MA,
USA), which cleaves only the CGCG sequence, which is not
converted by bisulphite treatment when methylated. To assess the
amount of methylation, the peak height of the product at 183bp
was divided by the sum of the peak heights at 183 and 186bp.
The resulting percentage of methylation was corrected for the
percentage of tumour cells. Most tumours with methylation of the
MLH1 promoter showed percentage of methylation above 80%,
whereas in none of the adjacent normal tissues methylation was
detected.
Patient characteristics and pedigree analysis
The following information was obtained for all families as part of
the genetic counselling procedure: age at diagnosis, type of cancer,
number of family members who had cancer, their age at diagnosis,
their type of cancer, and their relation with the patient.
Pathological and surgical reports were evaluated whenever
possible.
Pedigrees were scored as fulfilling the Amsterdam I criteria
(Vasen et al, 1991), the Amsterdam II criteria (Vasen et al, 1999),
or the criterion described by Rodriguez-Bigas et al (1997) that is:
two first degree relatives with a cancer associated with Lynch
syndrome, one of them with an age at diagnosis below 50 years.
As this study was mainly directed at MSI in tumours, a positive
score for fulfilment of one of these three criteria was only given if
the index patient was part of the criterion. The occurrence of
metachronous or synchronous cancers associated with Lynch
syndrome was noted.
Data analysis
Descriptive statistics were used to describe the results of the
molecular laboratory tests, germline mutation analysis, and
pedigree analysis. Categorical variables were checked for statisti-
cally significant differences using either the w
2 test or logistic
regression. Continuous variables were checked for statistically
significant differences using either the Student’s t-test or analysis
of variance. The Tukey–Kramer test was used to calculate
differences in continuous variables between two groups with
adjustment for multiple testing. P-values o0.05 were considered
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system for Windows V8.2.
RESULTS
Identification and characterisation of families with a
germline MMR gene mutation
Our strategy 1 involved germline mutation analysis without prior
testing for MSI in those families that fulfilled clinical criteria for
Lynch syndrome, and those for whom no tumour DNA was
available for MSI analysis. We found a germline mutation in 31 out
of these 83 families (Figure 1, Table 1). In total, 43 index patients
were tested for MSI within this group. MSI was detected in tumours
of 17/43 patients. In all 17 MSI-positive index patients, a germline
mutation in MLH1, MSH2,o rMSH6 was identified. One MSH2
mutation was detected in a patient with an endometrial tumour
diagnosed at age 39 that was tested MSI negative without loss of
MLH1, PMS2, MSH2, or MSH6 protein staining. No other tumours
from this family were available. One MSH6 mutation was detected in
a patient in whom a rectum tumour at an age of 51 years was MSI
negative without loss of MLH1, PMS2, MSH2, or MSH6 protein
staining. Material from a sigmoid carcinoma that occurred in
another family member at the age of 33 years was not available.
Strategy 2 involved 531 families clinically suspected of Lynch
syndrome. Here, a positive MSI test result was used to select
families for germline mutation analysis. In 86/531 families, at least
one MSI-positive tumour was detected. Although their tumours
were MSI positive, three patients declined testing for germline
mutations and for MLH1 promoter methylation in their tumour. In
the remaining 83 families, 45 MMR gene germline mutations were
detected (Table 1).
Thus, a pathogenic germline mutation was found in 76 out of
614 families (12%) with a clinical history suggestive of Lynch
syndrome. There were 24 mutations in MLH1, two in PMS2,3 2i n
MSH2, and 18 in MSH6.
Most MSI-positive tumours were also tested by IHC. Tumour
cells of MLH1 mutation carriers generally lacked MLH1 and
PMS2 protein by IHC staining. Those of MSH2 mutation carriers
lacked MSH2 and MSH6. Tumours of MSH6 mutation carriers
lacked MSH6, and those of PMS2 mutation carriers lacked
PMS2. The IHC pattern correctly pinpointed the mutated gene in
50 of the 53 tumours (94%) where IHC was sufficiently
informative.
We tested whether MLH1 promoter methylation occurs in the
presence of a germline mutation in one of the MMR genes. This
was found to be a rare event. We tested a total of 42 microsatellite
instable tumours from families with a germline mutation in MLH1
(13), PMS2 (1), MSH2 (14), or MSH6 (14). In only one of these
tumours (a tumour with an MSH6 germline mutation and absence
of MSH6 protein staining, but presence of MLH1 protein staining),
we detected incomplete MLH1 promoter methylation (about 60%).
Table 1 presents the results of analysis of MLH1 promoter
hypermethylation of index patients.
The majority (66%) of the proven Lynch syndrome families
(50/76) fulfilled the Amsterdam II criteria. This was true for both
strategy 1 (87%) and for strategy 2 (51%). The mean age at
diagnosis of the index patients was 44 years (42 and 46 years in
strategy 1 and 2, respectively).
Identification and characterisation of families with
hypermethylation of the MLH1 promoter in their tumour
Pathogenic germline mutations in the MMR genes could not be
detected in 38 families with at least one MSI-positive tumour
(Figure 1). We therefore examined the methylation status of the
MLH1 promoter in 42 MSI-positive tumours of these 38 families.
Methylation of the MLH1 promoter was detected in 22 tumours
(20 families) (Table 2). In the corresponding normal tissues
MLH1 promoter methylation was never detected, suggesting that
the promoter methylation was not present in the germline.
Lynch suspected index patients 
n=614
Mutation (n=45) 
MLH1 14 
MSH2 18 
MSH6 11 
PMS2 2
Strategy 1: 
Mutation analysis  
without preselection by MSI  
n=83
MSI analysis 
n=43
No MSI analysis 
n=40
MSI positive 
n=17
MSI negative 
n=26
Mutation (n=12) 
MLH1 7 
MSH2 4 
MSH6 1
Mutation (n=17) 
MLH1 3 
MSH2 9 
MSH6 5
Mutation (n=2) 
MSH2 1 
MSH6 1
Strategy 2: 
Preselection by MSI 
n=531
MSI negative  
n=445 
MSH6 mutation analysis 
n=92
MSI positive 
n=86 
Mutation analysis 
n=83
Somatic 
hypermethylation 
MLH1 promoter 
n=20
Unexplained MMR 
deficiency 
n=18
Figure 1 Analytic strategy of the study and number of patients in each analysis and for each result.
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sTable 1 Molecular laboratory tests results and patient characteristics of 76 patients with a pathogenic germline mutation in MLH1, PMS2, MSH2, or MSH6
No. S Germline mutation MSI Meth IHC Tumour tested for MSI Age Other tumour(s) AC 2fam
MLH1
8 1 c.15_28del (p.Gly6fs) NT NT NT 42 co42,co47 + +
288 2 c.18_34del (p.Val7fs) +   MLH1/PMS2  Caecum 40     
189 2 c.211_213del (p.Glu71del) +   PMS2/MSH6  Endometrium 39     
118 1 c.299C4T (p.Arg100X) NT NT NT 26 co26,co37 + +
645 2 c.578C4G (p.Ser193X) +   MLH1/PMS2  Caecum 26 co37,co39   +
163 1 c.588+3_588+6del (affects ss) NT NT NT 50 co50,co50,co50 + +
198 2 c.677G4A (p.Arg226Gln) (affects ss) +   MLH1/PMS2  Colon descendens 41   ++
318 2 c.806C4G (p.Ser269X) +   MLH1/PMS2  Colon transversum 59 en49,co27   +
19 1 c.806C4G (p.Ser269X) NT NT NT 45 co45 + +
345 2 c.1225C4T (p.Gln409X) +   MLH1/PMS2  Sigmoid 44   ++
454 2 c.1354del (p.Thr452fs) +   MLH1/PMS2  Colon transversum 49   ++
335 2 c.1549G4T (p.Gly517X) +   MLH1/PMS2  Sigmoid 49   ++
734 2 c.1852_1854del (p.Lys618del) + NT MLH1/PMS2  Urothelial cell carcinoma 60 co40,en54   +
428 2 c.1852_1854del (p.Lys618del) + NT MLH1/PMS2  Caecum 50 + +
15 1 c.1852_1854del (p.Lys618del) + NT MLH1/PMS2  Endometrium 52 ov52,co52   +
451 2 c.1852_1854del (p.Lys618del)
a +   MLH1na/PMS2  Colon ascendens 27     
168 2 c.1852_1854del (p.Lys618del) + NT NT Caecum 42   ++
42 1 c.1852_1854del (p.Lys618del) NT NT NT 36 co36 + +
3 1 c.1852_1854del (p.Lys618del) + NT NT Colon NOS 32   ++
324 2 c.2103+1G4A+   MLH1/PMS2  Flexura linealis 50 co50 + +
392 2 c.2103+1G4A+   MLH1/PMS2  Colon ascendens 38   ++
65 1 c.2103+1G4A+   MLH1/PMS2  Rectum 42   ++
222 1 c.2103+1G4A NT NT NT 38 co38 + +
260 1 c.2103+1G4A NT NT NT 55 co55,en61 + +
PMS2
386 2 entire gene deletion +   PMS2  Colon ascendens 36     
641 2 c.989–296_1144+706del + NT PMS2  Trichoepithelioma/trichoblastoma 45     
MSH2
322 2 c.1-?_211+?del + NT MSH2/MSH6  Colon ascendens 58 ur49 + +
92 1 c.1-?_211+?del + NT MSH2/MSH6  Endometrium 41   ++
5 1 c.1-?_211+?del + NT NT 38 co42 + +
614 2 c.1-?_366+?del + NT MSH2/MSH6  Flexura lienalis 21     
730 2 c.1-?_1076+?del + NT MSH2/MSH6  Urothelial cell carcinoma 57 co42 + +
528 2 c.1-?_1076+?del
b + NT none  Caecum 32 en44   +
139 1 c.1-?_1076+?del + NT MSH2/MSH6  Endometrium 41 co42 + +
287 2 c.1-?_1276+?del +   MSH2/MSH6  Caecum 33   ++
700 2 c.212–1G4A + NT MSH2-/MSH6na Caecum 52 co61   +
350 2 c.212-?_366+?del +   MSH6  Caecum 72   ++
117 1 c.212-?_366+?del +   MSH2/MSH6  Ileocecum 48   ++
73 1 c.212-?_366+?del + NT NT Colon ascendens 44 en37,ov37 + +
237 2 c.255dup (p.Glu86X) + NT MSH2/MSH6  Sebaceuous gland carcinoma 39 co25 + +
190 2 c.367-?_645+?del +   MSH2/MSH6  Caecum 50 co50,co50   
210 2 c.367-?_645+?del +   MSH2/MSH6  Colon transversum 43   ++
366 2 c.642_645del (p.Gln215X) + NT MSH2/MSH6  Flexura linealis 46   ++
18 1 c.793-?_1076+?del +   MSH2/MSH6  Rectum 29 co29 + +
25 1 c.836del (p.Leu279fs)
c +   MSH2/MSH6  Flexura linealis 46   ++
37 1 c.862C4T (p.Gln288X) NT NT NT 26 co26 + +
196 2 c.915_922dup (p.Arg308fs) + NT MSH2/MSH6  Sigmoid 46 co46   
11 1 c.943-?_1076+?del +   MSH2/MSH6  Endometrium 45   ++
14 1 c.1147C4T (p.Arg383X) NT NT NT 33 en33,co50 + +
497 2 c.1165C4T (p.Arg389X) + NT MSH2 /MSH6na Flexura lienalis 44     
462 2 c.1203dup (p.Gln402fs) +   MSH2/MSH6  Sigmoid 37   ++
74 1 c.1203dup (p.Gln402fs) +   MSH2 /MSH6na Rectum 32   ++
654 1 c.1255C4T (p.Gln419X) NT NT NT 45 co45,co63 + +
301 2 c.1277–2A4G + NT MSH2/MSH6  Caecum 33    +
637 2 c.1386+1G4T+   MSH2/MSH6  Colon transversum 47 co42   +
625 2 c.1387-?_1510+?del +   MSH2/MSH6  Endometrium 45 co53 + +
107 1 c.1494dup (p.Ala499fs) NT NT NT 46 co46 + +
327 2 c.1861C4T (p.Arg621X) + NT MSH2/MSH6  Sigmoid 58     
480 1 c.2005+1G4C   NT none  Endometrium 39 co45 + +
MSH6
206 1 c.1-?_457+?del
d + NT MSH6  Urothelial cell carcinoma 56 ur57   +
657 2 c.261-?_457+?dup
d + NT MSH6  Colon descendens 42   ++
745 2 c.467C4G (p.Ser156X) +   MSH6  Ileocecum 63   ++
138 2 c.651dup (p.Lys218X)
d +   MSH6  Sigmoid 52 en37 + +
342 1 c.814G4T (p.Glu272X)
d,f +   MSH6  Endometrium 57   ++
338 2 c.1135_1139del (p.Arg379X)
d +   MSH6  Endometrium 38 ov38   
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promoter methylation, we performed subsequent molecular
analyses of other tumours of index patients or family members.
Tumours either were MSI negative or showed methylation of the
MLH1 promoter in combination with absence of MLH1 protein
staining (Table 2).
The Amsterdam II criteria were met in 11 of the 20 families
(55%) with an MSI-positive tumour that was due to somatic
hypermethylation of the MLH1 promoter. The mean age at
diagnosis of these index patients was 61 years.
Characterisation of families with an unexplained
MSI-positive tumour
There were 18 families with MSI-positive tumours, where neither a
pathogenic MMR gene mutation was present, nor could hyper-
methylation of the MLH1 promoter be demonstrated in the tumour
(Table 3). These tumours were truly MSI positive, as in 17 of these
tumours more than 75% of markers were instable, whereas the
remaining tumour (no. 421) had three instable mononucleotide
and three stable dinucleotide markers.
Table 1 (Continued)
No. S Germline mutation MSI Meth IHC Tumour tested for MSI Age Other tumour(s) AC 2fam
137 1 c.1784del (p.Leu595fs)   NT none  Rectum 51 + +
515 2 c.2815C4T (p.Gln939X)
a,d + NT MSH6  Iieum 65 co38,co51,co58,ur69   +
105 1 c.3261del (p.Phe1088fs)
d +   MSH6  Colon ascendens 39   ++
766 2 c.3261del (p.Phe1088fs) +   MSH6  Endometrium 41     
446 2 c.3261dup (p.Phe1088fs)
d +   MSH2/MSH6  Endometrium 43   ++
450 2 c.3273dup (p.Lys1092X)
d +   MSH6  Colon ascendens 50 co46,co50 + +
711 2 c.3438+1G4A + NT MSH6na Rectum 45   ++
692 2 c.3438+1G4A + NT MSH6na Colon transversum 43 en53,ov43   
500 2 c.3514dup (p.Arg1172fs) + + MSH6  Colon transversum 70 ur70   
434 1 c.3678_3706dup (p.Ala1236fs)
d NT NT NT 38 en38   +
128 1 c.3838C4T (p.Gln1280X)
d +   MSH6  Endometrium 36   ++
886 1 c.4001G4A (p.Arg1334Gln) affects ss + NT MSH6na
e Colon NOS 44 co61: MSI pos,IHC MSH6 NA   +
S, strategy of molecular testing; MSI, microsatellite instability; Meth, methylation analysis of MLH1 promoter; IHC, immunohistochemical analysis of MLH1, PMS2, MSH2, and
MSH6; Tumour tested for MSI, tumour origin or exact location of tumour in case of colon cancer of tumour tested for MSI; Age, age at diagnosis of tumour tested for MSI or age
at diagnosis of (first) tumour in case MSI analysis was not performed; Other tumour(s), metachronous or synchronous cancer associated with Lynch syndrome of index patient
who had MSI analysis or tumour(s) of index patient who did not have MSI analysis and age at diagnosis; AC, Amsterdam II criteria (Vasen et al, 1999); 2fam, 2 first degree relatives
(including index) with cancer associated with Lynch syndrome, one of them with an age at diagnose below 50 years (Rodriguez-Bigas et al, 1997); 1, strategy 1 (germline mutation
analysis without preselection by MSI analysis); 2, strategy 2 (first MSI analysis); ss, splice site; +, positive;  , negative; NT, not tested; NA, not assessable; NOS, not otherwise
specified; co, colon; en, endometrium; ur, urothelial; ov, ovarian.
aCarrier status of patient deduced from mutation status of relatives.
bAlso carrier of variant c.1A4G (p.Met1?) in
MSH2 (paper in preparation).
cAlso carrier of variant c.965G4A(p.Gly322Asp) in MSH2.
dMutations published elsewhere (Kets et al, 2006).
eAdenocarcinoma Caecum of sister
with same mutation MSI and IHC MSH6  (1co46 MSI IHC MSH6 ).
fAlso carrier of variant c.65G4C (p.Gly22Ala) in MLH1.
Table 2 Molecular laboratory tests results and family history of 20 patients with an MSI-positive tumour with somatic MLH1 promoter methylation
No. Meth IHC Tumour tested for MSI Age Other tumour(s) AC 2fam Tumours of close relatives
312 + MLH1/PMS2  Caecum 63   + + 1co53 MSS
408 + MLH1/PMS2  Colon ascendens 62 co40 + +
642
a + MLH1/PMS2  Colon transversum 62 co62: MSI, IHC MLH1 , meth+    1co75 MSI,IHC: MLH1 ,meth+
477 + MLH1/PMS2  Colon transversum 75 co75    2co50 MSS
226 + MLH1/PMS2  Colon ascendens 67   ++
755 + MLH1/PMS2  Colorectum NOS 72 co72   
299 + MLH1/PMS2  Colon ascendens 50 co50 +   1co59 MSS
154 + MLH1/PMS2  Colon ascendens 71   + + 1co38 MSS
771 + MLH1/PMS2  Colon ascendens 65 co65   
683 + PMS2  Colon ascendens 69      1co58 MSS
785 + MLH1/PMS2  Colon descendens 54 co54   
142 + MLH1/PMS2  Colon ascendens 55 en57 + + 1co22 MSS
86 + MLH1/PMS2  Colon ascendens 55   ++
482
b + MLH1/PMS2  Caecum 65 co64 +  
748 + MLH1/PMS2  Colorectum NOS 45     
57 + MLH1/PMS2  Colon transversum 49   ++
441 + MLH1/PMS2  Caecum 51     
316 + MLH1/PMS2  Colon NOS 71 en70 MSS,co71 + + 2co43 MSS
331 + MLH1/PMS2  Duodenum 47     
655 + MLH1/PMS2/MSH2/MSH6  Colon descendens 64 co47 MSS, ur64 MSS + +
Meth, methylation analysis of MLH1 promoter; IHC, immunohistochemical analysis of MLH1, PMS2, MSH2, and MSH6; Tumour tested for MSI, tumour origin or exact location of
tumour in case of colon cancer of tumour tested for MSI; Age, age at diagnosis of tumour tested for MSI; Other tumour(s), metachronous or synchronous cancer associated with
Lynch syndrome of index patient and age at diagnosis; AC, Amsterdam II criteria (Vasen et al, 1999); 2fam, 2 first degree relatives (including index) with a Lynch syndrome
associated cancer, one of them with an age at diagnose below 50 years (Rodriguez-Bigas et al, 1997); Tumours of close relatives, tumours of close relatives tested for MSI and/or
IHC, meth; +, positive;  , negative; NOS, not otherwise specified; co, colon; en, endometrium; ur, urothelial; MSI, MSI positive; MSS, MSI negative; 1, first degree relative;2 ,
second degree relative. (e.g. 1co53 MSS, a first degree relative of index patient had a colon tumour diagnosed at the age of 53 years which was MSI negative).
aCarrier of
unclassified variant c.3744_3773dup (p.His1248_Ser1257dup) in MSH6.
bCarrier of unclassified variant c.663A4C (p.Glu221Asp) in MSH6.
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mutation in an MMR gene and without hypermethylation of the
MLH1 promoter, the staining of at least one MMR protein was
absent. The IHC patterns were in line with inactivation of MLH1
(five families), PMS2 (two families), MSH2 (six families), and
MSH6 (one family (no. 421)). In the last family, an unclassified
MSH6 variant was detected for which the pathogenic nature could
not be established (Kets et al, 2006). In two families, there was
simultaneous loss of IHC protein staining of MSH2 and MSH6, and
of PMS2.
Subsequent molecular analyses of tumours of family members of
these index patients are presented in Table 3. Two index patients
with absent MSH2 staining had a family member with a tumour
with an IHC pattern that also matched with MSH2 inactivation,
that is absence of MSH2 and MSH6.
Only two of the 18 families (11%) with an unexplained MSI-
positive tumour fulfilled the Amsterdam II criteria. The mean age
at diagnosis of these index patients was 44 years.
Sensitivity of current mutation detection techniques
Mutation analysis was performed in 100 families with at least one
tumour with MSI. In 20 of these families, MLH1 promoter
methylation was present. A pathogenic germline mutation was
detected in 62 of the remaining 80 families (78%). Mostly, their
clinical characteristics matched those of classical Lynch syndrome:
a germline mutation was detected in 36 of 38 (95%) of those
families that fulfilled the Amsterdam II criteria. Likewise, an MMR
gene mutation was found in 47 of 54 (87%) of the families that met
the following criterion of the Bethesda guidelines: two first degree
relatives (including the index patient) with a tumour associated
with Lynch syndrome, of which at least one was diagnosed below
the age of 50 years.
Comparison of characteristics of families with and without
a detectable MMR gene mutation
The majority of families with an MMR gene mutation fulfilled the
Amsterdam II criteria. In the 83 families selected by MSI only
(strategy 2), we found that the clinical Amsterdam II criteria were
met in 51% of the families in which an MMR gene mutation was
eventually found compared with 11% of those in whom no such
mutation was detected (Po0.009). The mean age at onset of the
index patients was comparable in both groups (46 and 44 years,
respectively). The mean age at diagnosis of index patients with a
tumour with somatic hypermethylation of the MLH1 promoter (61
years) was significantly higher than that of mutation positive index
patients (Table 4).
DISCUSSION
A disease causing germline mutation was identified in 78% of
patients suspected of Lynch syndrome with an MSI-positive
tumour and absence of hypermethylation of the MLH1 promoter.
Interestingly, the remaining 22% of patients with an unexplained
MSI-positive tumour had a less pronounced family history of
cancer, but were diagnosed at an age comparable with that of
proven Lynch syndrome patients. Assessment bias is not likely to
cause this difference, as the criteria for family history of cancer
only include data from close relatives that should be known by the
index patients. The large majority of the tumours in this group
without gene mutations or promoter methylation, nonetheless
showed loss of IHC staining of at least one of the MMR proteins.
This is highly suggestive for the presence of either a germline
mutation or of a somatic inactivation of the gene involved. These
families had a much less prominent history of cancer, which might
suggest the presence of a different type of mutation with a lower
risk of cancer for relatives. Our current mutation detection
protocol, which was highly effective in the classical Lynch
syndrome families, did not pick up such putative mutations in
this cohort.
The putative mutations might include (1) point mutations in the
PMS2 gene that are known to have a lower cancer risk (Truninger
et al, 2005; Worthley et al, 2005; Hendriks et al, 2006); (2) germline
methylation of the MSH2 promoter as was recently described
(Chan et al, 2006); (3) mutations in regulatory sequences or
missence variants that might lead to a lower risk of tumour
Table 3 Molecular laboratory tests results and family history of 18 patients with an MSI-positive tumour with unexplained etiology
No. Meth IHC Tumour tested for MSI Age Other tumour(s) AC 2fam Tumours of close relatives
149
a   MLH1/PMS2  Colon ascendens 43      3co45 MSS
499   MLH1/PMS2  Colon ascendens 58     
445   MLH1/PMS2  Colon transversum 49    +
498   MLH1/PMS2  Sigmoid 58 co49   
172   MLH1/PMS2  Colon ascendens 51    +
373
a   PMS2  Caecum 36     
554   PMS2  Colon transversum 55 co55    1co56 MSS
582   MSH2/MSH6  Sigmoid 33   + + 1co47 MSI,IHC:MSH2 ,meth 
396   MSH2/MSH6  Appendix 34     
224   MSH2/MSH6  Ileocecum 53 co34,co50 + +
580   MSH2/MSH6  Endometrium 45     
718   MSH2/MSH6  Rectum 18    + 1co47 MSI,HC:MSH2 ,meth 
736   MSH2/MSH6  Rectum 58 co58 MSS   
421
b   MSH6  Colon ascendens 53      1en62 MSI/IHC NA
135   PMS2/MSH2/MSH6 
c Colon ascendens 27     
243   PMS2/MSH2/MSH6 
c Colon transversum 30    +
127   None  Rectum 54     
375
d   None  Caecum 36    +
Meth, methylation analysis of MLH1 promoter; IHC, immunohistochemical analysis of MLH1, PMS2, MSH2, and MSH6; Tumour tested for MSI, tumour origin or exact location of
tumour in case of colon cancer of tumour tested for MSI; Age, age at diagnosis of tumour tested for MSI; Other tumour(s), metachronous or synchronous cancer associated with
Lynch syndrome of index patient and age at diagnosis; AC, Amsterdam II criteria (Vasen et al, 1999). 2fam, 2 first degree relatives (including index) with Lynch syndrome
associated cancer, one of them with an age at diagnose below 50 years (Rodriguez-Bigas et al, 1997); Tumours of close relatives, tumours of close relatives tested for MSI and/or
IHC, meth; +, positive;  , negative; NA, not assessable; co, colon; MSI, MSI positive; MSS, MSI negative; 1, first degree relative; 2, second degree relative; 3 third degree relative.
(e.g. 3co45 MSS, a third degree relative of index patient had a colon tumour diagnosed at the age of 45 years which was MSI negative).
aCarrier of unclassified variant
c.1852_1853delinsGC (p.Lys618Ala) in MLH1.
bCarrier of unclassified variant c.2117T4C (p.Phe706Ser) in MSH6 (Kets et al, 2006).
cIHC difficult to interpret.
dCarrier of
unclassified variant c.250A4G (p.Lys84Glu) in MLH1 and c.984C4T (silent) in MSH2.
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affected MMR gene might be more dependent on modifier genes;
and (4) a type of mutation that frequently arises de novo.
To our knowledge, this is the first study in which the difference
in family history between patients with unexplained MSI-positive
tumours and patients with a recognised germline mutation is
addressed. The underlying mechanism for the familial occurrence
of a tumour with MSI in such families remains unknown.
Irrespective of this, confirmation for these findings in future
studies might suggest that the clinical management in these
families needs to be modified. For the time being, our surveillance
advice for patients with an unexplained MSI-positive tumour and
their close relatives remains identical to that of patients with Lynch
syndrome including the start of surveillance at an early age.
The present study shows that the currently used techniques to
detect a germline mutation have a sensitivity of 78% for patients
with an MSI-positive tumour without hypermethylation of the
MLH1 promoter. A similar percentage can be calculated from data
published by Hampel et al (2005): after exclusion of MSI-positive
tumours with methylation of the MLH1 promoter, they found a
germline mutation in 23 out of 29 patients (79%) with an MSI-
positive tumour. Their methods to analyse germline mutations are
comparable with those used in our study. The sensitivity of
germline mutation detection could not be deduced from other
studies, as they did not include analysis of hypermethylation of the
MLH1 promoter and/or performed less comprehensive germline
mutation analyses (Mangold et al, 2005; Barnetson et al, 2006;
Niessen et al, 2006). Wagner et al (2003) also found a difference in
prevalence of pathogenic MLH1, MSH2,o rMSH6 mutations
between families that fulfilled the Amsterdam criteria (39
mutations in 49 families (80%)) and those not fulfilling these
criteria (five mutations in 10 families (50%)) using methods that
detect a similar type of mutations as the methods used in the
present study. However, in this study data about the MMR
deficiency of the tumours are missing.
In conclusion, this is the first study showing that almost all
highly penetrant MMR gene mutations are identified with the
currently used germline mutation detection techniques. The
sensitivity of the currently used germline mutation detection
techniques is at least 78% and probably near 100% in Lynch
syndrome families with a highly penetrant mutation. A minority of
MSI-positive tumours may be due to germline mutations in MMR
genes that cannot yet be detected. Such putative mutations may
confer a lower risk of cancers associated with Lynch syndrome for
relatives.
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